Trimmed population | Stratified-matched population | |||||
---|---|---|---|---|---|---|
Rituximab (n = 265) | Anti-TNF (n = 737) | Standardized difference | Rituximab (n = 205) | Anti-TNF (n = 205) | Standardized difference | |
Demographics | ||||||
White, % | 87.6 | 83.5 | 0.114 | 84.4 | 87.3 | 0.084 |
Female, % | 81.1 | 79.2 | 0.049 | 82.9 | 81.0 | 0.051 |
Age, mean (SD), years | 57.8 (11.7) | 56.1 (12.4) | 0.139 | 57.6 (11.7) | 58.0 (11.5) | 0.037 |
Insurance | ||||||
Medicare, % | 37.7 | 29.4 | 0.176 | 33.7 | 39.0 | 0.111 |
Medicaid, % | 7.2 | 6.4 | 0.032 | 7.3 | 6.3 | 0.039 |
Private insurance, % | 76.6 | 78.7 | 0.050 | 76.1 | 74.6 | 0.034 |
No insurance, % | 1.1 | 2.3 | 0.090 | 1.5 | 1.5 | 0.000 |
History of comorbidities | ||||||
Cardiovascular disease, % | 11.3 | 7.3 | 0.137 | 9.8 | 11.7 | 0.063 |
Cancer, % | 9.4 | 7.7 | 0.061 | 10.2 | 8.8 | 0.050 |
Diabetes, % | 9.8 | 10.7 | 0.030 | 10.2 | 10.7 | 0.016 |
Clinical characteristics | ||||||
Disease duration, mean (SD), years | 15.4 (10.2) | 11.4 (9.4) | 0.408 | 14.6 (10.3) | 15.1 (10.5) | 0.047 |
Tender joint count, mean (SD) | 9.6 (7.3) | 8.7 (7.3) | 0.117 | 9.5 (7.2) | 9.1 (7.8) | 0.058 |
Swollen joint count, mean (SD) | 8.0 (5.6) | 7.5 (5.7) | 0.097 | 7.9 (5.5) | 7.4 (5.8) | 0.086 |
Patient global assessment, mean (SD) | 54.3 (23.6) | 50.6 (25.0) | 0.154 | 53.2 (23.4) | 52.7 (25.5) | 0.023 |
Physician global assessment, mean (SD) | 42.7 (20.2) | 39.3 (20.1) | 0.169 | 42.3 (19.7) | 39.8 (19.1) | 0.130 |
Patient pain, mean (SD) | 56.5 (24.5) | 53.2 (25.5) | 0.132 | 55.3 (24.8) | 53.0 (26.2) | 0.093 |
Disability index (mHAQ), mean (SD) | 0.78 (0.5) | 0.64 (0.5) | 0.270 | 0.74 (0.5) | 0.72 (0.5) | 0.040 |
Clinical Disease Activity Index, mean (SD) | 27.3 (12.5) | 25.2 (11.9) | 0.172 | 27.0 (12.0) | 25.7 (12.3) | 0.100 |
Prior medication use | ||||||
Prior nbDMARDs, n, mean | 1.6 | 1.1 | 0.396 | 1.4 | 1.4 | 0.031 |
Prior use of ≥2 anti-TNF agents, % | 63.0 | 26.6 | 0.786 | 54.6 | 54.6 | 0.000 |
Prior use of non–anti-TNF biologic agents, % | 40.8 | 13.0 | 0.657 | 31.7 | 33.2 | 0.031 |
Concomitant medications | ||||||
Prednisone, % | 43.8 | 29.3 | 0.303 | 39.0 | 38.5 | 0.010 |
Methotrexate, % | 57.7 | 55.9 | 0.037 | 57.1 | 51.7 | 0.108 |
Non-methotrexate nbDMARD, % | 29.1 | 24.8 | 0.095 | 29.8 | 30.2 | 0.011 |